1 results match your criteria: "New York Presbyterian-Weill Medical Cornell Medical Center[Affiliation]"
Clinical pharmacology of GW280430A in humans.
Anesthesiology
April 2004
Department of Anesthesiology, New York Presbyterian-Weill Medical Cornell Medical Center, New York, New York 10021, USA.
Background: An ultrashort-acting nondepolarizing neuromuscular blocking agent that could be an alternative to succinylcholine has been the focus of a concerted effort in the field of muscle relaxants. GW280430A showed a promising pharmacodynamic profile in preclinical work and a wide margin of safety and so was selected for study in humans.
Methods: Thirty-one volunteers participated in this study, which determined the dose producing 95% block (ED95) and the safety and pharmacodynamics of increasing ED95 multiples.